May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 14, 2025

Leading Cause of Death in Residents, Study

Study shows high suicide rates during training transitions, with pathology residents facing the highest suicide risk compared with other specialties.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 29, 2025

RadSearch Transforms Radiology Report Retrieval 

RadSearch could enhance radiologists' ability to find precedent cases.

Conexiant

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 22, 2025

Role of Pathologists in Improving Access to Safer, More Effective Allogeneic Cell Therapies

Researchers are working to accelerate the clinical adoption of novel allogeneic cell therapies to improve cancer care and treatment.

The ASCO Post

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant